Source: Pharma Biz
InnoCare receives China NMPA approval for phase III trial of mesutoclax with azacitidine versus venetoclax with azacitidine to treat naive AML
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the Center for Drug Evaluation (CDE) of the China National Medical Products
Key Points
- InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the Center for Drug Evaluation (CDE) of the China National Medical Products
Published: August 20, 2026 12:30 pm
Source: Pharma Biz